Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.55 |
| ▸ | ULK1 | O75385 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | CCR4 | P51679 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 6/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.32 |
| ▸ | UBE2M | P61081 | 1/20 | 0.32 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4649712 | 0.97 | CNR2 (0.54) | CNR2ULK1PIK3CAEGFRCCR4 | |
| SCHEMBL4649177 | 0.82 | CNR2 (0.63) | CNR2ULK1PIK3CA | |
| SCHEMBL4648963 | 0.80 | KDM4E (0.46) | CNR2EGFR | |
| SCHEMBL4649715 | 0.80 | CNR2 (0.61) | CNR2ULK1PIK3CAEGFREPHX2 | |
| Hydrochloric Acid SCHEMBL4649618 | 0.80 | CNR2 (0.60) | CNR2ULK1PIK3CAEPHX2 | |
| SCHEMBL14005975 | 0.79 | CNR2 (0.51) | CNR2ULK1PIK3CAEGFREPHX2 | |
| SCHEMBL4650258 | 0.77 | CNR2 (0.33) | CNR2 | |
| SCHEMBL4649736 | 0.77 | CDK4 (0.38) | CNR2PIK3CAEGFRSLC6A2SLC6A4 | |
| SCHEMBL4649071 | 0.77 | CNR2 (0.37) | CNR2 | |
| SCHEMBL14006010 | 0.76 | CNR2 (0.61) | CNR2ULK1PIK3CAEGFRSOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280868-A1 | Pyridine Derivatives and Their Use as Cb2 Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| EP-1718613-B1 | PYRIDINE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2008-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280868-A1 | Pyridine Derivatives and Their Use as Cb2 Receptor Modulators | CNR2, CNR1, TRPV1 | CNR2 1/4885ULK1 1154/4885PIK3CA 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.